ArticleBlood advances2022
Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Non-viral TcBuster transposon engineering of CD70-CAR natural killer cells for the treatment of osteosarcoma.Molecular therapy. Oncology · 2026Article
- Advances in Nanotechnology for Lymphoma Treatment: Targeted Delivery, Immunomodulation, and TME-Responsive Therapy Strategies.International journal of nanomedicine · 2026Review
- Cellular and molecular aberrations generating new immunotherapeutic approaches in mycosis fungoides and Sézary syndrome: a comprehensive review of literature.Frontiers in immunology · 2026Review
- Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.Journal of personalized medicine · 2025Review
- CD70: An emerging target for integrated cancer diagnosis and therapy.Clinical and translational medicine · 2025Review
- New and emerging therapies in cutaneous T-cell lymphoma.Dermatology reports · 2025Article
- Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).Current hematologic malignancy reports · 2025Review
- Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.The Lancet. Oncology · 2025Article
- Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents.Virchows Archiv : an international journal of pathology · 2024Article
- Antibody-Based Therapies for Peripheral T-Cell Lymphoma.Cancers · 2024Review
- CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy.Blood advances · 2024Article
- Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma.Journal of hematology & oncology · 2024Review
- Single cells and TRUST4 reveal immunological features of the HFRS transcriptome.Frontiers in medicine · 2024Article
- "Next top" mouse models advancing CTCL research.Frontiers in cell and developmental biology · 2024Review
- CAR-T Cell Therapy for T-Cell Malignancies.Mediterranean journal of hematology and infectious diseases · 2024Review
- Review
- The functional and clinical roles of liquid biopsy in patient-derived models.Journal of hematology & oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD70 is a member of the tumor necrosis factor receptor superfamily. Emerging data indicate that CD70 may be a suitable target for various malignancies. We investigated the expression of CD70 in cutaneous and systemic T-cell lymphomas and conducted preclinical studies of SGN-CD70A, a CD70-directed antibody-drug conjugate (ADC), using patient-derived xenograft cutaneous T-cell lymphoma (CTCL PDX) models. CD70 expression was examined by immunohistochemical (IHC) stains in 49 diagnostic specimens of T-cell lymphomas. The activities of SGN-CD70A in growth inhibition and apoptosis induction were examined in CTCL cell lines and primary CTCL tumor cells. Using previously established CTCL PDXs, we conducted a dose-finding trial followed by a phase 2-like trial to evaluate the optimal dosing and the efficacy of SGN-CD70A in tumor-bearing PDX animals. The therapeutic efficacy of SGN-CD70A was measured by tumor-associated cell-free DNA (cfDNA) and survival of treated PDXs. We found that CD70 is highly expressed in T-cell lymphomas, especially in CTCL. SGN-CD70A inhibited cell growth and induced apoptosis in CD70-expressing CTCL cell lines and primary tumors cells. Additionally, SGN-CD70A at 100 μg/kg and 300 μg/kg prolonged the survival of PDXs in a dose-dependent manner. Finally, treatment with 3 doses of SGN-CD70A at 300 μg/kg was superior to a single-dose treatment in survival prolongation (median survival: 111 days vs 39 days; P = .017). Most importantly, multiple dosing of SGN-CD70A induced complete eradication of established tumors in PDXs measured by cfDNA. Our results demonstrated marked antitumor activity of SGN-CD70A in CTCL PDXs, providing compelling support for its clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.